報價延遲最少15分鐘:2026/04/16 00:35 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
23 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-23.04/-0.21
|
|
企業價值
111.37M
|
| 資產負債 |
|
每股賬面淨值
11.59
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Pelthos Therapeutics Inc is a biopharmaceutical company committed to commercializing safe and efficacious therapeutic products to help patients with unmet treatment burdens. The Company currently has three U.S. Food and Drug Administration(FDA) approved products in its commercial portfolio, in various stages of commercialization, including ZELSUVMITM, XEPI, and XEGLYZE. The company operates in two reporting segments: the sale, promotion, and commercialization of approved commercial products, the Commercial Operations segment, and research and development activities related to developing a novel and proprietary class of NaV blockers that target the body's peripheral nervous system; and supportive activities toexpand the NITRICIL nitric oxide-based technology. |
